Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma

  • Iris Rabinovich | iris_rbv@yahoo.com.br Pontifical Catholic University of Paraná, Department of Health Sciences, Brazil.
  • Ana Paula Martins Sebastião Federal University of Paraná, Department of Pathology, Brazil.
  • Rubens Silveira Lima Pontifical Catholic University of Paraná, Department of Health Sciences, Brazil.
  • Cícero de Andrade Urban Positivo University, Department of Scientific Methodology, Brazil.
  • Eduardo Schunemann Junior Federal University of Paraná, Department of Tocogynecology, Brazil.
  • Karina Furlan Anselmi Positivo University, Department of Scientific Methodology, Brazil.
  • Selene Elifio-Esposito Pontifical Catholic University of Paraná, Department of Health Sciences, Brazil.
  • Lucia de Noronha Pontifical Catholic University of Paraná, Department of Health Sciences, Brazil.
  • Andréa Novais Moreno-Amaral Pontifical Catholic University of Paraná, Department of Health Sciences, Brazil.

Abstract

Breast cancer is a very heterogeneous disease. The intrinsic molecular subtypes can explain the intertumoral heterogeneity and the cancer stem cell (CSC) hypothesis can explain the intratumoral heterogeneity of this kind of tumor. CD44+/CD24- phenotype and ALDH1 expression are the major CSC markers described in invasive breast cancer. In the present study, 144 samples of invasive breast carcinoma, no special type were distributed in 15 tissue microarrays (TMA) and then evaluated for expression of the CD44+/CD24- phenotype and ALDH1 to understand the importance of these CSC markers and the clinical aspects of breast cancer. The samples were classified into four molecular subtypes according to clinicopathological criteria: Luminal A, Luminal B, HER2, and Basal-like. A statistical association was found between the molecular subtypes and the CSC markers, with HER2 the most frequent subtype for both markers. ALDH1 was also associated with other poor prognostic variables, such as a high histological grade and larger tumors, but it was not associated with the patients’ prognosis in this sample and nor was the CD44+/CD24- phenotype in a multivariate analysis. There are still many controversies about the role of these markers in breast cancer molecular subtypes. The identification of these populations of cells, through immunohistochemical markers, can help to better understand the CSC theory in clinical practice and, in the near future, contribute to developing new target therapies.

   

Downloads

Download data is not yet available.
Published
2018-09-03
Section
Original Papers
Keywords:
Breast cancer, CD44 /CD24- phenotype, ALDH1, molecular subtypes, cancer stem cells
Statistics
Abstract views: 491

PDF: 249
HTML: 18
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Rabinovich, I., Sebastião, A. P. M., Lima, R. S., Urban, C. de A., Junior, E. S., Anselmi, K. F., Elifio-Esposito, S., de Noronha, L., & Moreno-Amaral, A. N. (2018). Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. European Journal of Histochemistry, 62(3). https://doi.org/10.4081/ejh.2018.2943